AngioDynamics (ANGO) vs Daxor (DXR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
AngioDynamics (ANGO) has outperformed Daxor (DXR) over the past year, gaining 1.0% versus a loss of 20.0%. Over five years, DXR leads with a -7.0% price change compared with -59.0% for ANGO. AngioDynamics is the larger company by market cap ($472.3 million vs $61.1 million), about 7.7 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANGO | DXR |
|---|---|---|
| Share price | $11.23 | $10.46 |
| Market cap | $472.27M | $61.07M |
| 1-day change | -20.86% | +1.01% |
| YTD return | -12.54% | -29.08% |
| 1-year return | +0.99% | -20.03% |
| 5-year return | -58.97% | -7.02% |
| P/E ratio (TTM) | — | 9.51 |
| EPS (TTM) | $-0.88 | $1.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $16.29 | $14.76 |
| 52-week low | $9.39 | $8.56 |
| Distance from 52-week high | -31.06% | -29.13% |
| Analyst consensus | none | none |
| Avg. price target upside | +78.09% | +91.20% |
| Average volume | 557.83K | 17.27K |
| Shares outstanding | 42.05M | 5.84M |
| Employees | 632 | — |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AngioDynamics is about 7.7 times larger than Daxor by market value ($472.27M vs $61.07M).
- ANGO has outperformed DXR by 21.0 percentage points over the past year.
About AngioDynamics
ANGO stock →AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells products for the treatment of cardiovascular disease and cancer diagnoses in the United States and internationally. The company operates through Med Tech and Med Device segments.
Health Care · Medical/Dental Instruments · 632 employees
About Daxor
DXR stock →Daxor Corporation engages in medical instrumentation and biotechnology operations. It develops the BVA-100 Blood Volume Analyzer, an instrument that measures human blood volume, in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit.
Health Care · Medical/Dental Instruments
ANGO vs DXR FAQ
Which is bigger, AngioDynamics or Daxor?
AngioDynamics (ANGO) is larger, with a market capitalization of $472.27M compared with $61.07M for Daxor (DXR).
Which stock has performed better over the past year, ANGO or DXR?
ANGO returned +0.99% over the past 12 months, compared with -20.03% for DXR (price return, excluding dividends). Past performance does not predict future results.
Are AngioDynamics and Daxor in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.